Letícia Marina da Silva

Ms. Letícia Marina da Silva

Universidade Estadual do Centro-Oeste, Guarapuava, Paraná, Brazil
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Jeferson ZiebarthJeferson Ziebarth
Jeferson Ziebarth
Letícia Marina da SilvaLetícia Marina da Silva
Letícia Marina da Silva
Ariane Krause Padilha LorenzettAriane Krause Padilha Lorenzett
Ariane Krause Padilha Lorenzett
IFIngrid Delbone Figueiredo
Ingrid Delbone Figueiredo
PCPaulo Fernando Carlstrom
Paulo Fernando Carlstrom
Rubiana Mara MainardesRubiana Mara Mainardes
Rubiana Mara Mainardes
Liraglutide (LIRA) is a glucagon-like peptide-1 (GLP-1) receptor agonist renowned for its efficacy in treating type 2 diabetes mellitus (T2DM) and is typically administered via subcutaneous injections. Oral delivery, although more desirable for being painless and potentially enhancing patient adherence, is challenged by the peptide’s low bioavailability and vulnerability to digestive enzymes. This study aimed to develop LIRA-containing zein-based nanoparticles stabilized with eudragit RS100 and chitosan for oral use (Z-ERS-CS/LIRA). These nanoparticles demonstrated a spherical shape, with a mean diameter of 238.6 nm, a polydispersity index of 0.099, a zeta potential of +40.9 mV, and an encapsulation efficiency of 41%. In vitro release studies indicated a prolonged release, with up to 61% of LIRA released over 24 h. Notably, the nanoparticles showed considerable resistance and stability in simulated gastric and intestinal fluids, suggesting protection from pH and enzymatic degradation. Pharmacokinetic analysis revealed that orally administered Z-ERS-CS/LIRA paralleled the pharmacokinetic profile seen with subcutaneously delivered LIRA. Furthermore, in vivo tests on a diabetic rat model showed that Z-ERS-CS/LIRA significantly controlled glucose levels, comparable to the results observed with free LIRA. The findings underscore Z-ERS-CS/LIRA nanoparticles as a promising approach for oral LIRA delivery in T2DM management.